Mountain Group Partners Completes Fundraising on $128 Million MGP Venture Fund III

NASHVILLE, Tenn.–(BUSINESS WIRE)–Mountain Group Partners (“Mountain Group” or the “Firm”), a Nashville-based venture capital firm, announced the closing of an above target amount of $128 million in its third fund (“MGP Fund III”). Mountain Group will continue its strategy of investing in early-stage companies within human and animal life sciences and disruptive technologies. “We are … [Read more…]

Dunad Therapeutics Appoints Industry Veteran Pearl Huang as Chief Executive Officer

Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad appoints new CEO as company establishes U.S. operations, continues to expand its platform based on novel insights into covalent chemistry and build its internal drug discovery programs CAMBRIDGE, England–(BUSINESS WIRE)–Dunad … [Read more…]

Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus

Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results Priovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting … [Read more…]

Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma

– Pivotal ZUMA-5 Study Demonstrates Overall Response Rate of 91% and a Complete Response rate of 77% in Patients Who Received Yescarta After Three or More Lines of Therapy – – Kite’s Third Approved Cell Therapy Indication in Europe – SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission … [Read more…]

French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats

In response to strong results, the Agency has extended DNA Script’s contract SOUTH SAN FRANCISCO, Calif. & PARIS–(BUSINESS WIRE)–#DNASynthesis–DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System … [Read more…]

Global Wearable Medical Devices Market to 2027 – Featuring Fitbit, Phillips and Garmin Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Wearable Medical Devices Market to 2027” report has been added to ResearchAndMarkets.com’s offering. Wearable medical devices are the type of handheld monitoring tools which are used in monitoring and identification of diseases. The demand for wearable medical devices are continuously increasing in the market, where disposable income, innovations, and technological advancements are … [Read more…]

UbiPharm and Imperial Form Strategic Alliance to Create One of Africa’s most Expansive Healthcare Distribution Networks

ROUEN, France–(BUSINESS WIRE)–This strategic alliance formed by UbiPharm and Imperial, both significant logistics and distribution players in the healthcare industry in Africa, will provide complementary continental route-to-market solutions to healthcare principals and clients, leveraging best-in-class operations and commercial services. While UbiPharm and Imperial will each maintain their individual business autonomies, the strategic alliance will drive … [Read more…]

Confo Therapeutics Awarded EUR 1.7M VLAIO Grant to Expand Application of ConfoBody® Drug Discovery and Development Technology in Rare Diseases

GHENT, Belgium–(BUSINESS WIRE)–Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the purpose of developing needed new … [Read more…]

Turkish Medical Team Separates Conjoined Twins in 9 Hours, Breaking World Record

The team led by Prof. Karaaltin, employed revolutionary techniques to save lives of conjoined twins ISTANBUL–(BUSINESS WIRE)–A Turkish medical team has successfully separated conjoined twins shortly after birth by employing a range of innovative techniques, including virtual simulations and 3D modeling. Carried out at Istanbul’s Acibadem Hospital, the successful procedure set a new world record … [Read more…]

Iktos Announces Collaboration With Galapagos in AI For Drug Design

PARIS–(BUSINESS WIRE)–Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a collaboration with Galapagos, a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, to apply Iktos’s generative modelling artificial intelligence (AI) technology in one of Galapagos drug discovery programs. Under the agreement, Iktos will apply … [Read more…]